论文部分内容阅读
目的:观察大剂量阿糖胞苷治疗早期急性淋巴细胞白血病的疗效。方法:将急性淋巴细胞白血病57例,随机分为对照组26例和观察组31例。对照组采用常规联合化疗方案治疗;观察组在对照组治疗方案的基础上,前3个疗程采用大剂量阿糖胞苷强化治疗。比较两组6个月、1年和3年生存率,3年复发率和不良反应。结果:观察组6个月1、年生存率与对照组比较,差异不显著(P>0.05),3年生存率显著高于对照组(P<0.05);3年复发率显著低于对照组(P<0.05);两组不良反应比较,差异不显著(P>0.05)。结论:大剂量阿糖胞苷强化治疗早期急性淋巴细胞白血病疗效优于常规联合化疗。
Objective: To observe the efficacy of high-dose cytarabine in the treatment of early acute lymphoblastic leukemia. Methods: Fifty-seven acute lymphoblastic leukemia patients were randomly divided into control group (n = 26) and observation group (n = 31). The control group was treated with conventional combination chemotherapy; the observation group was treated with high dose of cytarabine in the first three courses on the basis of the control group. The 6-month, 1-year and 3-year survival rates, 3-year relapse rates and adverse reactions were compared between the two groups. Results: The 6-month survival rate in the observation group 1 was significantly lower than that in the control group (P> 0.05), and the 3-year survival rate was significantly higher than that in the control group (P <0.05). The 3-year recurrence rate was significantly lower than that in the control group (P <0.05). There was no significant difference between the two groups in adverse reactions (P> 0.05). CONCLUSION: High-dose cytarabine is superior to conventional combination chemotherapy in the treatment of early-stage acute lymphoblastic leukemia.